Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
Vatiquinone (formerly also known as EPI-743) is anovel, potent and orally bioavailable cellular oxidative stress protectant and a para-benzoquinone analog being developed for treating inherited mitochondrial diseases. The mechanism of action of EPI-743 involves augmenting the synthesis of glutathione, optimizing metabolic control, enhancing the expression of genetic elements critical for cellular management of oxidative stress, and acting at the mitochondria to regulate electron transport. Leigh syndrome is a mitochondrial disease caused by respiratory chain deficiency, and there are no proven effective therapies. EPI-743 is a potent cellular oxidative stress protectant and results of clinical trials for mitochondrial diseases are accumulating.
ln Vitro |
Ferroptosis is a type of lipid- and iron-dependently regulated cell death linked to lipoxygenase-induced lipid peroxide generation and glutathione depletion. In fibroblasts from PCH6 patients, EPI-743 inhibits RSL3-induced ferroptosis with an average EC50 potency value of 17.3-21.8 nM [3]. EPI-743 inhibits BODIPY 581/591 C11 lipid oxidation at 37, 111, and 333 nM for a 24-hour period [3]. The efficient prevention of ferroptosis caused by RSL3 (2 μM), FeC (100 μM), and BSO (50 μM) can be achieved with EPI-743 (0.1 nM-1 mM; 48 hours) [3]. In PCH6 patient fibroblasts, EPI-743 (1 μM, 3 hours) is reduced to EPI-743 hydroquinone (EPI-743-HQ), and EPI-743-HQ (0.1-100 μM; 30 minutes) suppresses human activity. The 15-LO enzyme's activity inhibition rate is 20% at 100 μM, with an IC50 of 4.4 μM [3].
|
---|---|
Cell Assay |
Cell Viability Assay[3]
Cell Types: Primary fibroblasts and B lymphocytes Tested Concentrations: 0-1 mM Incubation Duration: 48 hrs (hours) Experimental Results: Inhibition of RSL3-mediated ferroptotic cell death in B lymphocytes in a dose-dependent manner . Viability was restored to levels comparable to untreated cells, indicating complete rescue. |
References |
[1]. Kouga T, et al. Japanese Leigh syndrome case treated with EPI-743. Brain Dev. 2018 Feb;40(2):145-149. Brain Dev. 2018 Feb;40(2):145-149.
[2]. Avula S, et al. Treatment of Mitochondrial Disorders. Curr Treat Options Neurol. 2014. 16:292. [3]. Kahn-Kirby AH, et al. Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy. PLoS One. 2019 Mar 28;14(3):e0214250. |
Molecular Formula |
C29H44O3
|
---|---|
Molecular Weight |
440.657869338989
|
Exact Mass |
440.33
|
Elemental Analysis |
C, 79.04; H, 10.06; O, 10.89
|
CAS # |
1213269-98-7
|
Appearance |
Oily liquid (sizes under 1g will be supplied in ethanol at 10mg/mL)
|
SMILES |
O=C1C(CC[C@](C)(O)CC/C=C(C)/CC/C=C(C)/CC/C=C(C)\C)=C(C)C(C(C)=C1C)=O
|
InChi Key |
LNOVHERIIMJMDG-XZXLULOTSA-N
|
InChi Code |
InChI=1S/C29H44O3/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8,32)19-17-26-25(7)27(30)23(5)24(6)28(26)31/h12,14,16,32H,9-11,13,15,17-19H2,1-8H3/b21-14+,22-16+/t29-/m1/s1
|
Chemical Name |
2-((R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione
|
Synonyms |
EPI743; ATQ3; EPI-743; ATQ-3; EPI 743; alpha-Tocotrienol quinone. ATQ 3
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~226.93 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.67 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.67 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2693 mL | 11.3466 mL | 22.6932 mL | |
5 mM | 0.4539 mL | 2.2693 mL | 4.5386 mL | |
10 mM | 0.2269 mL | 1.1347 mL | 2.2693 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.